Novel C-C chemokine receptor 2 antagonists in metabolic disease: A review of recent developments

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

Introduction: C-C chemokine ligand 2 (CCL2), also known as monocyte chemoattractant protein-1, and its receptor, C-C chemokine receptor 2 (CCR2), play important roles in various inflammatory diseases. Recently, it has been reported that the CCL2/CCR2 pathway also has an important role in the pathogenesis of metabolic syndrome through its association with obesity and related systemic complications. Areas covered: This review focuses on the roles of CCR2 in the pathogenesis of adipose tissue inflammation and other organ damage associated with metabolic syndrome, which is still a matter of debate in many studies. It also covers the use of novel CCR2 antagonists as therapies in such conditions. Expert opinion: There is abundant experimental evidence that the CCL2/CCR2 pathway may be involved in chronic low-grade inflammation of adipose tissue in obesity and related metabolic diseases. Although animal models of diabetes and obesity, as well as human trials, have produced controversial results, there is continued interest in the roles of CCR2 inhibition in metabolic disease. Further identification of the mechanisms for recruitment and activation of phagocytes and determination of the roles of other chemokines are needed. Future study of these fundamental questions will provide a clearer understanding of adipose tissue biology and potential therapeutic targets for treatment of obesity-related metabolic disease, including diabetic nephropathy.

Original languageEnglish
Pages (from-to)745-756
Number of pages12
JournalExpert Opinion on Investigational Drugs
Volume20
Issue number6
DOIs
Publication statusPublished - 2011 Jun 1

Fingerprint

C Chemokines
CC Chemokines
Chemokine Receptors
Metabolic Diseases
Obesity
Adipose Tissue
Ligands
CCR2 Receptors
Inflammation
Expert Testimony
Diabetic Nephropathies
Phagocytes
Chemokines
Therapeutics
Animal Models

Keywords

  • CCR2 antagonist
  • chemokine ligand 2
  • chemokine receptor 2
  • diabetic nephropathy
  • dipose tissue macrophage
  • insulin resistance
  • metabolic syndrome
  • obesity

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Novel C-C chemokine receptor 2 antagonists in metabolic disease : A review of recent developments. / Kang, Young Sun; Cha, Jin Joo; Hyun, Young Youl; Cha, Dae-Ryong.

In: Expert Opinion on Investigational Drugs, Vol. 20, No. 6, 01.06.2011, p. 745-756.

Research output: Contribution to journalReview article

@article{068aee2dae934146ae8b47c6d9d85f57,
title = "Novel C-C chemokine receptor 2 antagonists in metabolic disease: A review of recent developments",
abstract = "Introduction: C-C chemokine ligand 2 (CCL2), also known as monocyte chemoattractant protein-1, and its receptor, C-C chemokine receptor 2 (CCR2), play important roles in various inflammatory diseases. Recently, it has been reported that the CCL2/CCR2 pathway also has an important role in the pathogenesis of metabolic syndrome through its association with obesity and related systemic complications. Areas covered: This review focuses on the roles of CCR2 in the pathogenesis of adipose tissue inflammation and other organ damage associated with metabolic syndrome, which is still a matter of debate in many studies. It also covers the use of novel CCR2 antagonists as therapies in such conditions. Expert opinion: There is abundant experimental evidence that the CCL2/CCR2 pathway may be involved in chronic low-grade inflammation of adipose tissue in obesity and related metabolic diseases. Although animal models of diabetes and obesity, as well as human trials, have produced controversial results, there is continued interest in the roles of CCR2 inhibition in metabolic disease. Further identification of the mechanisms for recruitment and activation of phagocytes and determination of the roles of other chemokines are needed. Future study of these fundamental questions will provide a clearer understanding of adipose tissue biology and potential therapeutic targets for treatment of obesity-related metabolic disease, including diabetic nephropathy.",
keywords = "CCR2 antagonist, chemokine ligand 2, chemokine receptor 2, diabetic nephropathy, dipose tissue macrophage, insulin resistance, metabolic syndrome, obesity",
author = "Kang, {Young Sun} and Cha, {Jin Joo} and Hyun, {Young Youl} and Dae-Ryong Cha",
year = "2011",
month = "6",
day = "1",
doi = "10.1517/13543784.2011.575359",
language = "English",
volume = "20",
pages = "745--756",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Novel C-C chemokine receptor 2 antagonists in metabolic disease

T2 - A review of recent developments

AU - Kang, Young Sun

AU - Cha, Jin Joo

AU - Hyun, Young Youl

AU - Cha, Dae-Ryong

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Introduction: C-C chemokine ligand 2 (CCL2), also known as monocyte chemoattractant protein-1, and its receptor, C-C chemokine receptor 2 (CCR2), play important roles in various inflammatory diseases. Recently, it has been reported that the CCL2/CCR2 pathway also has an important role in the pathogenesis of metabolic syndrome through its association with obesity and related systemic complications. Areas covered: This review focuses on the roles of CCR2 in the pathogenesis of adipose tissue inflammation and other organ damage associated with metabolic syndrome, which is still a matter of debate in many studies. It also covers the use of novel CCR2 antagonists as therapies in such conditions. Expert opinion: There is abundant experimental evidence that the CCL2/CCR2 pathway may be involved in chronic low-grade inflammation of adipose tissue in obesity and related metabolic diseases. Although animal models of diabetes and obesity, as well as human trials, have produced controversial results, there is continued interest in the roles of CCR2 inhibition in metabolic disease. Further identification of the mechanisms for recruitment and activation of phagocytes and determination of the roles of other chemokines are needed. Future study of these fundamental questions will provide a clearer understanding of adipose tissue biology and potential therapeutic targets for treatment of obesity-related metabolic disease, including diabetic nephropathy.

AB - Introduction: C-C chemokine ligand 2 (CCL2), also known as monocyte chemoattractant protein-1, and its receptor, C-C chemokine receptor 2 (CCR2), play important roles in various inflammatory diseases. Recently, it has been reported that the CCL2/CCR2 pathway also has an important role in the pathogenesis of metabolic syndrome through its association with obesity and related systemic complications. Areas covered: This review focuses on the roles of CCR2 in the pathogenesis of adipose tissue inflammation and other organ damage associated with metabolic syndrome, which is still a matter of debate in many studies. It also covers the use of novel CCR2 antagonists as therapies in such conditions. Expert opinion: There is abundant experimental evidence that the CCL2/CCR2 pathway may be involved in chronic low-grade inflammation of adipose tissue in obesity and related metabolic diseases. Although animal models of diabetes and obesity, as well as human trials, have produced controversial results, there is continued interest in the roles of CCR2 inhibition in metabolic disease. Further identification of the mechanisms for recruitment and activation of phagocytes and determination of the roles of other chemokines are needed. Future study of these fundamental questions will provide a clearer understanding of adipose tissue biology and potential therapeutic targets for treatment of obesity-related metabolic disease, including diabetic nephropathy.

KW - CCR2 antagonist

KW - chemokine ligand 2

KW - chemokine receptor 2

KW - diabetic nephropathy

KW - dipose tissue macrophage

KW - insulin resistance

KW - metabolic syndrome

KW - obesity

UR - http://www.scopus.com/inward/record.url?scp=79955830809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955830809&partnerID=8YFLogxK

U2 - 10.1517/13543784.2011.575359

DO - 10.1517/13543784.2011.575359

M3 - Review article

C2 - 21466412

AN - SCOPUS:79955830809

VL - 20

SP - 745

EP - 756

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 6

ER -